FR04C0010I1 - - Google Patents
Info
- Publication number
- FR04C0010I1 FR04C0010I1 FR04C0010C FR04C0010I1 FR 04C0010 I1 FR04C0010 I1 FR 04C0010I1 FR 04C0010 C FR04C0010 C FR 04C0010C FR 04C0010 I1 FR04C0010 I1 FR 04C0010I1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16988993A | 1993-12-17 | 1993-12-17 | |
PCT/US1994/014497 WO1995016679A1 (fr) | 1993-12-17 | 1994-12-13 | Antagonistes de recepteurs des tachykinines, a base de morpholine et thiomorpholine |
Publications (2)
Publication Number | Publication Date |
---|---|
FR04C0010I1 true FR04C0010I1 (fr) | 2004-05-21 |
FR04C0010I2 FR04C0010I2 (fr) | 2004-12-17 |
Family
ID=22617632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR04C0010C Active FR04C0010I2 (fr) | 1993-12-17 | 2004-04-13 | Antagonistes de recepteurs des tachykinines, a base de morpholine |
Country Status (41)
Country | Link |
---|---|
EP (1) | EP0734381B1 (fr) |
JP (1) | JP3245424B2 (fr) |
KR (1) | KR100335704B1 (fr) |
CN (1) | CN1057296C (fr) |
AT (1) | ATE194336T1 (fr) |
AU (1) | AU701862B2 (fr) |
BG (1) | BG64775B1 (fr) |
BR (1) | BR9408351A (fr) |
CA (1) | CA2178949C (fr) |
CO (1) | CO4340628A1 (fr) |
CY (2) | CY2203B1 (fr) |
CZ (1) | CZ295381B6 (fr) |
DE (2) | DE69425161T2 (fr) |
DK (1) | DK0734381T3 (fr) |
ES (1) | ES2147840T3 (fr) |
FI (1) | FI109532B (fr) |
FR (1) | FR04C0010I2 (fr) |
GR (1) | GR3034095T3 (fr) |
HK (1) | HK1009046A1 (fr) |
HR (1) | HRP941000B9 (fr) |
HU (1) | HU224014B1 (fr) |
IL (1) | IL111960A (fr) |
LT (1) | LTC0734381I2 (fr) |
LU (1) | LU91069I9 (fr) |
LV (1) | LV11617B (fr) |
MY (1) | MY115164A (fr) |
NL (1) | NL300146I2 (fr) |
NO (3) | NO308742B1 (fr) |
NZ (1) | NZ278222A (fr) |
PL (1) | PL182521B1 (fr) |
PT (1) | PT734381E (fr) |
RO (1) | RO118203B1 (fr) |
RU (1) | RU2201924C2 (fr) |
SA (1) | SA95150523B1 (fr) |
SI (1) | SI0734381T1 (fr) |
SK (1) | SK282800B6 (fr) |
TW (1) | TW419471B (fr) |
UA (1) | UA47397C2 (fr) |
WO (1) | WO1995016679A1 (fr) |
YU (1) | YU49037B (fr) |
ZA (1) | ZA9410008B (fr) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1462450B1 (fr) * | 1993-12-29 | 2007-06-13 | MERCK SHARP & DOHME LTD. | Dérivés de morpholine substitués et leur application en tant qu'agents thérapeutiques |
TW385308B (en) * | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
AU690682B2 (en) * | 1994-05-05 | 1998-04-30 | Merck Sharp & Dohme Limited | Morpholine derivatives and their use as antagonists of tachikinins |
AU691327B2 (en) * | 1994-08-15 | 1998-05-14 | Merck Sharp & Dohme Limited | Morpholine derivatives and their use as therapeutic agents |
GB9417956D0 (en) * | 1994-09-02 | 1994-10-26 | Merck Sharp & Dohme | Therapeutic agents |
GB9505491D0 (en) * | 1995-03-18 | 1995-05-03 | Merck Sharp & Dohme | Therapeutic agents |
GB9511031D0 (en) * | 1995-06-01 | 1995-07-26 | Merck Sharp & Dohme | Chemical process |
GB9513118D0 (en) * | 1995-06-28 | 1995-08-30 | Merck Sharp & Dohme | Therapeutic agents |
GB9523244D0 (en) * | 1995-11-14 | 1996-01-17 | Merck Sharp & Dohme | Therapeutic agents |
US5750549A (en) * | 1996-10-15 | 1998-05-12 | Merck & Co., Inc. | Cycloalkyl tachykinin receptor antagonists |
ZA985765B (en) | 1997-07-02 | 1999-08-04 | Merck & Co Inc | Polymorphic form of a tachykinin receptor antagonist. |
WO1999001444A1 (fr) * | 1997-07-02 | 1999-01-14 | Merck & Co., Inc. | Forme polymorphe de l'antagoniste de recepteur de tachykinine 2-(r)-(1-(r) -(3,5-bis(trifluoromethyl) phenyl)ethoxy)-3-(s)-(4-fluoro) phenyl-4-(3-5 (-oxo-1h,4h-1,2,4,-triazolo) methylmorpholine |
GB9813025D0 (en) | 1998-06-16 | 1998-08-12 | Merck Sharp & Dohme | Chemical synthesis |
WO2000050398A2 (fr) * | 1999-02-24 | 2000-08-31 | F. Hoffmann-La Roche Ag | Derives de pyridinyl et de phenyle |
AU772446B2 (en) | 1999-02-24 | 2004-04-29 | F. Hoffmann-La Roche Ag | 3-phenylpyridine derivatives and their use as NK-1 receptor antagonists |
EP1035115B1 (fr) | 1999-02-24 | 2004-09-29 | F. Hoffmann-La Roche Ag | Dérivés de 4-phenylpyridine et leur utilisation comme antagonistes du recepteur NK-1 |
US6291465B1 (en) | 1999-03-09 | 2001-09-18 | Hoffmann-La Roche Inc. | Biphenyl derivatives |
DE60006340T2 (de) * | 1999-11-29 | 2004-09-09 | F. Hoffmann-La Roche Ag | 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramid |
US6452001B2 (en) | 2000-05-25 | 2002-09-17 | Hoffmann-La Roche Inc. | Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation |
US6482829B2 (en) | 2000-06-08 | 2002-11-19 | Hoffmann-La Roche Inc. | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor |
AR030284A1 (es) * | 2000-06-08 | 2003-08-20 | Merck & Co Inc | Proceso para la sintesis de (2r, 2-alfa-r,3a) -2-[1-(3,5-bis(trifluorometil) fenil) etoxi]-3-(4-fluorofenil)-1,4-oxazina; dicho compuesto y sus formas polimorficas |
WO2002006236A1 (fr) | 2000-07-14 | 2002-01-24 | F. Hoffmann-La Roche Ag | N-oxydes en tant que promedicaments de derives de 4-phenyl-pyridine, antagonistes du recepteur nk1 |
TWI287003B (en) | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
TWI259180B (en) | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
YU39503A (sh) | 2000-11-22 | 2006-05-25 | F. Hoffmann-La Roche Ag. | Derivati pirimidina |
US6642226B2 (en) | 2001-02-06 | 2003-11-04 | Hoffman-La Roche Inc. | Substituted phenyl-piperidine methanone compounds |
DK1390372T3 (da) | 2001-05-14 | 2008-09-15 | Hoffmann La Roche | 1-oxa-3,9-diaza-spiro '5,5]undecan-2-on-derivater og anvendelse deraf som neurokininreceptorantagonist |
US6849624B2 (en) | 2001-07-31 | 2005-02-01 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted amides |
US6638981B2 (en) | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
UA76810C2 (uk) * | 2001-12-10 | 2006-09-15 | Мерк Енд Ко., Інк. | Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок |
AR039625A1 (es) * | 2002-04-18 | 2005-03-02 | Merck & Co Inc | Proceso para la preparacion de 5-((2(r)--(1(r)- (3,5-bis (trifluormetil) fenil)etoxi-3 (s) - (4-fluorfenil) -4-morfolinil) metil) -1,2-dihidro-3h-1,2,4-triazol-3-ona |
NZ541243A (en) | 2003-01-31 | 2008-04-30 | Hoffmann La Roche | New crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1lambda6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide |
GB0310881D0 (en) * | 2003-05-12 | 2003-06-18 | Merck Sharp & Dohme | Pharmaceutical formulation |
JP4490421B2 (ja) | 2003-07-03 | 2010-06-23 | エフ.ホフマン−ラ ロシュ アーゲー | 統合失調症を処置するデュアルnk1/nk3アンタゴニスト |
TWI280239B (en) | 2003-07-15 | 2007-05-01 | Hoffmann La Roche | Process for preparation of pyridine derivatives |
ES2246687B2 (es) | 2004-02-11 | 2006-11-16 | Miguel Muñoz Saez | Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales. |
US7541357B2 (en) | 2004-07-15 | 2009-06-02 | Amr Technology, Inc. | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
JP4767973B2 (ja) | 2005-02-22 | 2011-09-07 | エフ.ホフマン−ラ ロシュ アーゲー | Nk1アンタゴニスト |
RU2404969C2 (ru) | 2005-03-23 | 2010-11-27 | Ф. Хоффманн-Ля Рош Аг | Метаболиты антагонистов nk-1 против рвоты |
ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
GEP20125566B (en) | 2005-07-15 | 2012-07-10 | Amr Technology Inc | Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
CN101267808A (zh) | 2005-09-23 | 2008-09-17 | 弗·哈夫曼-拉罗切有限公司 | 新型制剂 |
AU2006297443B2 (en) | 2005-09-29 | 2010-08-12 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
WO2007044829A2 (fr) | 2005-10-06 | 2007-04-19 | Dr. Reddy's Laboratories Ltd. | Preparation de l'aprepitant |
EP1984359A1 (fr) * | 2006-02-03 | 2008-10-29 | Glenmark Pharmaceuticals Limited | Formes amorphes et cristallines d'aprépitant et procédés pour leur préparation |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
WO2008026216A2 (fr) * | 2006-08-28 | 2008-03-06 | Hetero Drugs Limited | Procédé de purification d'aprépitant |
CA2664113C (fr) | 2006-09-22 | 2013-05-28 | Merck & Co., Inc. | Utilisation de la platencine et de la platensimycine en tant qu'inhibiteurs de la synthese des acides gras pour traiter l'obesite, lediabete et le cancer |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
CN101190330A (zh) | 2006-11-30 | 2008-06-04 | 深圳市鼎兴生物医药技术开发有限公司 | 胆碱酯酶在拮抗速激肽药物中的应用 |
JP4611444B2 (ja) | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤としてのアミド置換インダゾール |
WO2008090114A1 (fr) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Compositions pharmaceutiques contenant du 2-méthoxy-5- (5-trifluorométhyl-tétrazol-i-yl-benzyl) - (2s-phényl-pipéridin-3s-yl-) |
CA2682727C (fr) | 2007-04-02 | 2016-03-22 | Banyu Pharmaceutical Co., Ltd. | Derive d'indoledione |
JP5203449B2 (ja) | 2007-04-20 | 2013-06-05 | エフ.ホフマン−ラ ロシュ アーゲー | 二重nk1/nk3受容体アンタゴニストとしてのピロリジン誘導体 |
EP3103791B1 (fr) | 2007-06-27 | 2018-01-31 | Merck Sharp & Dohme Corp. | Dérivés de 4-carboxybenzylamino utilisés comme inhibiteurs de l'histone désacétylase |
RU2010106974A (ru) | 2007-08-07 | 2011-09-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Ариловые эфиры пирролидина в качестве антагонистов рецепторов nk3 |
CA2716080C (fr) | 2008-02-20 | 2016-12-13 | Targia Pharmaceuticals | Compositions pharmaceutiques actives sur le snc et methodes d'utilisation |
US8598184B2 (en) | 2008-03-03 | 2013-12-03 | Tiger Pharmatech | Protein kinase inhibitors |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
TW201031675A (en) | 2008-12-23 | 2010-09-01 | Pharmasset Inc | Synthesis of purine nucleosides |
AU2009329867B2 (en) | 2008-12-23 | 2015-01-29 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
WO2010114780A1 (fr) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibiteurs de l'activité akt |
CN102458123A (zh) | 2009-05-12 | 2012-05-16 | 阿尔巴尼分子研究公司 | 芳基、杂芳基和杂环取代的四氢异喹啉及其用途 |
PE20120373A1 (es) | 2009-05-12 | 2012-05-17 | Albany Molecular Res Inc | 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina |
WO2010132487A1 (fr) | 2009-05-12 | 2010-11-18 | Bristol-Myers Squibb Company | Formes cristallines de (s)-7-([1,2,4]triazolo[1,5-a] pyridin -6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline et leurs utilisations |
JP5099731B1 (ja) | 2009-10-14 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | p53活性を増大する置換ピペリジン及びその使用 |
HUE026235T2 (en) | 2010-03-31 | 2016-06-28 | Gilead Pharmasset Llc | Crystalline (S) -isopropyl 2 - (((S) - (((2R, 3R, 4R, 5R) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2H) -IL) - 4-Fluoro-3-hydroxy-4-methyltetrahydrofuran-2-IL) methoxy) (phenoxy) phosphoryl) amino) propanoate |
US8487102B2 (en) | 2010-04-20 | 2013-07-16 | Hoffmann-La Roche Inc. | Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists |
EP2584903B1 (fr) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk |
US8518907B2 (en) | 2010-08-02 | 2013-08-27 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
ES2376564B1 (es) | 2010-08-12 | 2013-01-24 | Manuel Vicente Salinas Martín | Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer. |
DK2606134T3 (da) | 2010-08-17 | 2019-07-22 | Sirna Therapeutics Inc | RNA-Interferens-formidlet inhibering af hepatitis-B-virus (HBV)-genekspression ved hjælp af kort interfererende nukleinsyre (siNA) |
EP2608669B1 (fr) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor |
WO2012030685A2 (fr) | 2010-09-01 | 2012-03-08 | Schering Corporation | Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk |
US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
JP5997162B2 (ja) | 2010-09-23 | 2016-09-28 | ナフォーミックス リミテッド | アプレピタントl−プロリン組成物および共結晶 |
DK2632472T3 (en) | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
EP2654748B1 (fr) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Dérivés d'indazole utiles en tant qu'inhibiteurs de erk |
US20140045847A1 (en) | 2011-04-21 | 2014-02-13 | Piramal Enterprises Limited | Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
WO2012146692A1 (fr) | 2011-04-29 | 2012-11-01 | Sandoz Ag | Nouveaux intermédiaires pour la préparation d'aprépitant ou de fosaprépitant de pureté élevée |
WO2013063214A1 (fr) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Nouveaux composés qui sont des inhibiteurs d'erk |
CN104159584A (zh) | 2011-11-25 | 2014-11-19 | 诺弗米克斯有限公司 | 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体 |
EP2837381A4 (fr) | 2011-12-13 | 2015-12-09 | Servicio Andaluz De Salud | Utilisation d'agents modificateurs de l'environnement péritumoral pour le traitement du cancer |
CZ304770B6 (cs) | 2012-03-13 | 2014-10-08 | Zentiva, K.S. | Způsob výroby 3-(((2R,3S)-2-((R)-1-(3,5-bis(trifluormethyl)fenyl)ethoxy)-3-(4-fluorfenyl)morfolino)methyl)-1H-1,2,4-triazol-5(4H)-onu (Aprepitantu) v polymorfní formě II |
EP3358013B1 (fr) | 2012-05-02 | 2020-06-24 | Sirna Therapeutics, Inc. | Compositions d'acide nucléique interférent court (sina) |
RU2660429C2 (ru) | 2012-09-28 | 2018-07-06 | Мерк Шарп И Доум Корп. | Новые соединения, которые являются ингибиторами erk |
AU2013352568B2 (en) | 2012-11-28 | 2019-09-19 | Merck Sharp & Dohme Llc | Compositions and methods for treating cancer |
ES2707305T3 (es) | 2012-12-20 | 2019-04-03 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de HDM2 |
WO2014120748A1 (fr) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2 |
ES2493693B1 (es) | 2013-02-11 | 2015-07-07 | Servicio Andaluz De Salud | Método para predecir o pronosticar la respuesta de un sujeto humano que padece un cáncer al tratamiento con un antagonista del receptor NK1 |
WO2015034925A1 (fr) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Polynucléotides circulaires |
CN103694146B (zh) * | 2013-12-04 | 2015-10-28 | 深圳万乐药业有限公司 | 2-(2-氯-1-亚乙基)酰肼甲酸甲酯的制备方法 |
ES2541870B1 (es) | 2013-12-27 | 2016-05-12 | Servicio Andaluz De Salud | Uso de antagonistas no peptídicos de NK1 en una determinada dosis para el tratamiento del cáncer |
TW201613888A (en) | 2014-09-26 | 2016-04-16 | Helsinn Healthcare Sa | Crystalline forms of an NK-1 antagonist |
US10005803B2 (en) | 2015-10-06 | 2018-06-26 | Helsinn Healthcare Sa | Crystalline forms of fosnetupitant |
BR112018074655B1 (pt) | 2016-06-06 | 2024-02-15 | Helsinn Healthcare Sa | Formulação injetável de fosnetupitanto, método de fabricação de uma formulação e uso de uma formulação injetável |
EP3706742B1 (fr) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Inhibiteurs de prmt5 |
EP3833667B1 (fr) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Inhibiteurs de prmt5 |
WO2020033282A1 (fr) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
BR112022018876A2 (pt) | 2020-04-03 | 2022-11-22 | Nerre Therapeutics Ltd | Antagonista de receptor de nk-1 para tratar uma doença selecionada a partir de sepse, choque séptico, síndrome de desconforto respiratório agudo (ards) ou síndrome de disfunção múltipla dos órgãos |
WO2021245512A1 (fr) | 2020-06-02 | 2021-12-09 | Nerre Therapeutics Limited | Antagonistes du récepteur de la neurokinine (nk)-1 destinés à être utilisés dans le traitement d'états de fibrose pulmonaire favorisés par une lésion mécanique des poumons |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0528495A1 (fr) * | 1991-08-20 | 1993-02-24 | Merck Sharp & Dohme Ltd. | Composés azacycliques, leur préparation et compositions pharmaceutiques les contenant |
IL106142A (en) * | 1992-06-29 | 1997-03-18 | Merck & Co Inc | Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them |
WO1994019323A1 (fr) * | 1993-02-18 | 1994-09-01 | Merck Sharp & Dohme Limited | Composes azacycliques, compositions contenant ces composes et leur utilisation comme antagonistes de la tachykinine |
-
1994
- 1994-12-12 IL IL11196094A patent/IL111960A/xx active Protection Beyond IP Right Term
- 1994-12-13 BR BR9408351A patent/BR9408351A/pt not_active Application Discontinuation
- 1994-12-13 PT PT95905965T patent/PT734381E/pt unknown
- 1994-12-13 AU AU14375/95A patent/AU701862B2/en not_active Expired
- 1994-12-13 NZ NZ278222A patent/NZ278222A/en not_active IP Right Cessation
- 1994-12-13 AT AT95905965T patent/ATE194336T1/de active
- 1994-12-13 JP JP51695995A patent/JP3245424B2/ja not_active Expired - Fee Related
- 1994-12-13 SK SK753-96A patent/SK282800B6/sk not_active IP Right Cessation
- 1994-12-13 CN CN94195008A patent/CN1057296C/zh not_active Expired - Lifetime
- 1994-12-13 RO RO96-01239A patent/RO118203B1/ro unknown
- 1994-12-13 DE DE69425161T patent/DE69425161T2/de not_active Expired - Lifetime
- 1994-12-13 LU LU91069C patent/LU91069I9/fr unknown
- 1994-12-13 CA CA002178949A patent/CA2178949C/fr not_active Expired - Lifetime
- 1994-12-13 EP EP95905965A patent/EP0734381B1/fr not_active Expired - Lifetime
- 1994-12-13 HU HU9601634A patent/HU224014B1/hu active Protection Beyond IP Right Term
- 1994-12-13 KR KR1019960703198A patent/KR100335704B1/ko not_active IP Right Cessation
- 1994-12-13 SI SI9430332T patent/SI0734381T1/xx unknown
- 1994-12-13 DE DE200412000019 patent/DE122004000019I1/de active Pending
- 1994-12-13 ES ES95905965T patent/ES2147840T3/es not_active Expired - Lifetime
- 1994-12-13 WO PCT/US1994/014497 patent/WO1995016679A1/fr active IP Right Grant
- 1994-12-13 UA UA96072833A patent/UA47397C2/uk unknown
- 1994-12-13 CZ CZ19961772A patent/CZ295381B6/cs not_active IP Right Cessation
- 1994-12-13 RU RU96115181/04A patent/RU2201924C2/ru active Protection Beyond IP Right Term
- 1994-12-13 DK DK95905965T patent/DK0734381T3/da active
- 1994-12-14 TW TW083111698A patent/TW419471B/zh not_active IP Right Cessation
- 1994-12-15 HR HRP941000AA patent/HRP941000B9/hr not_active IP Right Cessation
- 1994-12-15 ZA ZA9410008A patent/ZA9410008B/xx unknown
- 1994-12-16 CO CO94057019A patent/CO4340628A1/es unknown
- 1994-12-16 MY MYPI94003369A patent/MY115164A/en unknown
- 1994-12-16 YU YU74694A patent/YU49037B/sh unknown
-
1995
- 1995-03-14 SA SA95150523A patent/SA95150523B1/ar unknown
-
1996
- 1996-06-13 PL PL94315153A patent/PL182521B1/pl unknown
- 1996-06-14 FI FI962489A patent/FI109532B/fi active Protection Beyond IP Right Term
- 1996-06-14 NO NO962523A patent/NO308742B1/no not_active IP Right Cessation
- 1996-06-25 LV LVP-96-201A patent/LV11617B/en unknown
- 1996-07-16 BG BG100715A patent/BG64775B1/bg unknown
-
1998
- 1998-08-11 HK HK98109816A patent/HK1009046A1/xx not_active IP Right Cessation
-
2000
- 2000-08-02 GR GR20000401792T patent/GR3034095T3/el unknown
- 2000-11-24 CY CY0000056A patent/CY2203B1/xx unknown
-
2004
- 2004-04-05 NL NL300146C patent/NL300146I2/nl unknown
- 2004-04-13 FR FR04C0010C patent/FR04C0010I2/fr active Active
- 2004-04-21 NO NO2004003C patent/NO2004003I2/no unknown
- 2004-05-06 CY CY2004012C patent/CY2004012I2/el unknown
- 2004-05-07 LT LTPA2004002C patent/LTC0734381I2/lt unknown
-
2018
- 2018-04-04 NO NO2018011C patent/NO2018011I2/no unknown